↓ Skip to main content

ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

Overview of attention for article published in Molecular Cancer Therapeutics, July 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
4 news outlets
twitter
2 tweeters

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
Published in
Molecular Cancer Therapeutics, July 2020
DOI 10.1158/1535-7163.mct-19-1004
Pubmed ID
Authors

Lillian Skidmore, Sukumar Sakamuri, Nick A. Knudsen, Amha Gebre Hewet, Snezana Milutinovic, Wisam Barkho, Sandra Lyn Biroc, Jessica Kirtley, Robin Marsden, Kristine Storey, Ianina Lopez, Wayne Yu, Shiao-Yan Fang, Sulan Yao, Yi Gu, Feng Tian

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Other 6 17%
Student > Ph. D. Student 5 14%
Unspecified 3 8%
Student > Master 3 8%
Researcher 3 8%
Other 5 14%
Unknown 11 31%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 5 14%
Medicine and Dentistry 5 14%
Biochemistry, Genetics and Molecular Biology 4 11%
Agricultural and Biological Sciences 3 8%
Unspecified 3 8%
Other 4 11%
Unknown 12 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2022.
All research outputs
#1,153,006
of 21,168,082 outputs
Outputs from Molecular Cancer Therapeutics
#116
of 3,581 outputs
Outputs of similar age
#31,614
of 310,939 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#5
of 47 outputs
Altmetric has tracked 21,168,082 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,581 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,939 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.